SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients

Geers, Daryl, Shamier, Marc C., Bogers, Susanne, den Hartog, Gerco, Gommers, Lennert, Nieuwkoop, Nella N., Schmitz, Katharina S., Rijsbergen, Laurine C. +17 more·2021·Science Immunology
DOI 10.1126/sciimmunol.abj1750

Cited by (421)

Items 201–300 of 421

  1. SARS-CoV-2 vaccination elicits broad and potent antibody effector functions to variants of concern in vulnerable populations
    Andrew P. Hederman, Harini Natarajan, Leo Heyndríckx, Kevin K. Ariën, Joshua A. Wiener, Peter F. Wright, Evan M. Bloch, Aaron A.R. Tobian, Andrew D. Redd, Joel N. Blankson et al. · 2023 · Nature Communications
  2. In-depth analysis of T cell immunity and antibody responses in heterologous prime-boost-boost vaccine regimens against SARS-CoV-2 and Omicron variant
    Natalie Heinen, Corinna Sophie Marheinecke, Clara Bessen, Arturo Blazquez‐Navarro, Toralf Roch, Ulrik Stervbo, Moritz Anft, Carlos Plaza‐Sirvent, Sandra Buße, Mara Klöhn et al. · 2022 · Frontiers in Immunology
  3. Humoral and Cellular Responses to BNT162b2 as a Booster Following Two Doses of ChAdOx1 nCov-19 Determined Using Three SARS-CoV-2 Antibody Assays and an Interferon-Gamma Release Assay: A Prospective Longitudinal Study in Healthcare Workers
    Seri Jeong, Nuri Lee, Su Kyung Lee, Eun‐Jung Cho, Jungwon Hyun, Min-Jeong Park, Wonkeun Song, Hyun Soo Kim · 2022 · Frontiers in Immunology
  4. Dynamics of Antibody and T Cell Immunity against SARS-CoV-2 Variants of Concern and the Impact of Booster Vaccinations in Previously Infected and Infection-Naïve Individuals
    Michel R. Faas, Willem Ashwin Mak, Hilde Y. Markus, Ellen M. van der Zwan, Marijke van der Vliet, Johannes G.M. Koeleman, David S. Y. Ong · 2022 · Vaccines
  5. Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination
    Daryl Geers, Roos S. G. Sablerolles, Debbie van Baarle, Neeltje A. Kootstra, Wim J. R. Rietdijk, Katharina S. Schmitz, Lennert Gommers, Susanne Bogers, Nella J. Nieuwkoop, Laura L.A. van Dijk et al. · 2022 · iScience
  6. Booster COVID-19 mRNA vaccination ameliorates impaired B-cell but not T-cell responses in older adults
    Kohei Kometani, Takaaki Yorimitsu, Norihide Jo, Erina Yamaguchi, Osamu Kikuchi, Masaru Fukahori, Takeshi Sawada, Yoshitaka Tsujimoto, Ayana Sunami, Mengqian Li et al. · 2024 · Frontiers in Immunology
  7. Validation and performance evaluation of a novel interferon-γ release assay for the detection of SARS-CoV-2 specific T-cell response
    D. Huzly, M. Panning, Franziska Smely · 2021 · medRxiv
  8. Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response
    Federica Filippini, Mauro Giacomelli, Chiara Bazzani, Micaela Fredi, Paolo Semeraro, Cesare Tomasi, Franco Franceschini, Arnaldo Caruso, Ilaria Cavazzana, Cinzia Giagulli · 2023 · BMC Medicine
  9. Third SARS-CoV-2 Vaccination and Breakthrough Infections Enhance Humoral and Cellular Immunity Against Variants of Concern
    Louisa Ruhl, Jenny F. Kühne, Kerstin Beushausen, Jana Keil, Stella Christoph, Jasper Sauer, Christine Susanne Falk · 2022 · Frontiers in Immunology
  10. STING and TLR9 agonists synergistically enhance the immunogenicity of SARS-CoV-2 subunit vaccine
    Yang Li, Ziwei Chen, Xinyi Lu, Jiufeng Sun, Mengyu Guo, Huige Zhou, Ru Bai, Yuliang Zhao, Chunying Chen, Yaling Wang · 2023 · Nano Research
  11. A unique cytotoxic CD4 + T cell‐signature defines critical COVID‐19
    Sarah Baird, Caroline L. Ashley, Felix Marsh‐Wakefield, Sibel Alca, Thomas M. Ashhurst, Angela L. Ferguson, Hannah Lukeman, Claudio Counoupas, Jeffrey John Post, Pam Koneçny et al. · 2023 · Clinical & Translational Immunology
  12. IFN-γ-mediated control of SARS-CoV-2 infection through nitric oxide
    Bruno J. de Andrade Silva, Paul A. Krogstad, Rosane M. B. Teles, Priscila R. Andrade, Jacob Rajfer, Monica G. Ferrini, Otto O. Yang, Barry R. Bloom, Robert L. Modlin · 2023 · Frontiers in Immunology
  13. Adaptive immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infection
    Han-Sol Park, Janna R. Shapiro, Ioannis Sitaras, Bezawit A. Woldemeskel, Caroline C. Garliss, Amanda Dziedzic, Jaiprasath Sachithanandham, Anne Jedlicka, Christopher A. Caputo, Kimberly E. Rousseau et al. · 2022 · JCI Insight
  14. Cellular and humoral immunogenicity of the COVID-19 vaccine and COVID-19 disease severity in individuals with immunodeficiency
    Cliodhna E. Murray, C. O’Brien, S. Alamin, Stuart Hendricken Phelan, R. Argue, Rachel Kiersey, M. Gardiner, A. Naughton, E. Keogh, P. Holmes et al. · 2023 · Frontiers in Immunology
  15. COVID‐19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)‐T‐cell therapy
    Eleftheria Kampouri, Joshua Aiden Hill, M. Veronica Dioverti · 2023 · Transplant Infectious Disease
  16. Assessment of hybrid population immunity to SARS-CoV-2 following breakthrough infections of distinct SARS-CoV-2 variants by the detection of antibodies to nucleoprotein
    G. den Hartog, S. Andeweg, C. Hoeve · 2023 · Scientific Reports
  17. Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in eliciting cross-reactive memory B cells to Omicron subvariants
    Holly A. Fryer, Daryl Geers, Lennert Gommers, Luca M. Zaeck, Ngoc H. Tan, Bernadette Jones, Abraham Goorhuis, Douwe F. Postma, Leo G. Visser, Philip Mark Hogarth et al. · 2024 · Journal of Infection
  18. The effectiveness of the first dose COVID-19 booster vs. full vaccination to prevent SARS-CoV-2 infection and severe COVID-19 clinical event: a meta-analysis and systematic review of longitudinal studies
    Junjie Xu, Xinquan Lan, Liangyuan Zhang, Xiangjun Zhang, Jiaqi Zhang, Moxin Song, Jiaye Liu · 2023 · Frontiers in Public Health
  19. Highly conserved Betacoronavirus sequences are broadly recognized by human T cells
    Tertuliano Alves Pereira Neto, Christian M. Zmasek, Liliana Avalos, John Sidney, Raphael Trevizani, Elizabeth Jane Phillips, Simon Alexander Mallal, April Frazier, Gene S. Tan, Richard H. Scheuermann et al. · 2025 · Cell
  20. COVID-19 Prevention in Solid Organ Transplant Recipients
    Maria Tsikala-Vafea, Ghady Haidar · 2023 · Infectious Disease Clinics of North America
  21. T cell responses to SARS-CoV-2 in humans and animals
    Sameer-ul-Salam Mattoo, Jinjong Myoung · 2022 · The Journal of Microbiology
  22. Immunity in SARS-CoV-2 Infection: Clarity or Mystery? A Broader Perspective in the Third Year of a Worldwide Pandemic
    Katarzyna Kapten, Krzysztof Orczyk, Elżbieta Barbara Smolewska · 2023 · Archivum Immunologiae et Therapiae Experimentalis
  23. A Comprehensive Analysis of Structural and Functional Changes Induced by SARS-CoV-2 Spike Protein Mutations
    A. G. Mushebenge, S. Ugbaja, N. A. Mbatha · 2023 · COVID
  24. Comprehensive Analysis of CD4+ T Cell Response Cross-Reactive to SARS-CoV-2 Antigens at the Single Allele Level of HLA Class II
    You‐Seok Hyun, Yong‐Hun Lee, Hyeong-A Jo, In‐Cheol Baek, Sun-Mi Kim, Hyun‐Jung Sohn, Tai‐Gyu Kim · 2022 · Frontiers in Immunology
  25. T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern
    Hila Cohen, Shahar Rotem, Uri Elia, Gal Bilinsky, Itzchak Levy, Theodor Chitlaru, Erez Bar‐Haim · 2022 · Viruses
  26. Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON trial protocol
    Ngoc H. Tan, Roos S. G. Sablerolles, Wim J. R. Rietdijk, Abraham Goorhuis, Douwe F. Postma, Leo G. Visser, Susanne Bogers, Daryl Geers, Luca M. Zaeck, Marion Koopmans et al. · 2022 · Frontiers in Immunology
  27. Generating and measuring effective vaccine-elicited HIV-specific CD8+ T cell responses
    Gina M. Borgo, Rachel Lena Rutishauser · 2023 · Current Opinion in HIV and AIDS
  28. Degenerate CD8 Epitopes Mapping to Structurally Constrained Regions of the Spike Protein: A T Cell-Based Way-Out From the SARS-CoV-2 Variants Storm
    Carolina Boni, Davide Cavazzini, Angelo Bolchi, Marzia Rossi, Andrea Lorenzo Vecchi, Camilla Tiezzi, Valeria Barili, Paola Fisicaro, Carlo I. Ferrari, Simone Ottonello · 2021 · Frontiers in Immunology
  29. Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated
    Jill Maaske, Stephanie Sproule, Ann Regina Falsey, Magdalena E. Sobieszczyk, Anne F. Luetkemeyer, Grant C. Paulsen, Sharon A. Riddler, Merlin Lee Robb, Charlotte-Paige Rolle, Beverly E. Sha et al. · 2023 · Frontiers in Immunology
  30. mRNA-1273 vaccinated inflammatory bowel disease patients receiving TNF inhibitors develop broad and robust SARS-CoV-2-specific CD8+ T cell responses
    Jet van den Dijssel, Mariël C Duurland, Veronique A. L. Konijn, Laura Y. L. Kummer, Ruth R. Hagen, Lisan H Kuijper, Luuk Wieske, Koos P J van Dam, Eileen W Stalman, Maurice Steenhuis et al. · 2024 · Journal of Autoimmunity
  31. Breadth and Durability of SARS-CoV-2-Specific T Cell Responses following Long-Term Recovery from COVID-19
    Thi Thu Thao Dang, Alitzel Anzurez, Kaori Nakayama‐Hosoya, Shoji Miki, Kazuo Yamashita, Mark S. de Souza, Tetsuro Matano, Ai Kawana‐Tachikawa · 2023 · Microbiology Spectrum
  32. Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination
    Jordan J. Clark, Irene Hoxie, Daniel C. Adelsberg et al. · 2024 · bioRxiv
  33. Towards novel nano-based vaccine platforms for SARS-CoV-2 and its variants of concern: Advances, challenges and limitations
    Sally A. Helmy, Rasha M. EL Morsi, Soha M. El-Masry, Soha M. El-Masry · 2022 · Journal of Drug Delivery Science and Technology
  34. Development of T cell antigen-based human coronavirus vaccines against nAb-escaping SARS-CoV-2 variants
    Hao Zhou, Ping Leng, Yang Wang, Kaiwen Yang, Chen Li, David M. Ojcius, Pengfei Wang, Shibo Jiang · 2024 · 中国科学通报：英文版
  35. RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge
    Ting Y. Wong, Brynnan P. Russ, Katherine S. Lee, Olivia A. Miller, Jason H. Kang, Melissa Cooper, Michael T. Winters, Sergio A. Rodriguez‐Aponte, Neil C. Dalvie, Ryan S. Johnston et al. · 2022 · mSphere
  36. Omicron Sub-Lineage BA.5 and Recombinant XBB Evasion from Antibody Neutralisation in BNT162b2 Vaccine Recipients
    Martina Brandolini, Giulia Gatti, Laura Grumiro, Silvia Zannoli, Valentina Arfilli, Monica Cricca, Giorgio Dirani, Agnese Denicolò, Maria Michela Marino, Martina Manera et al. · 2023 · Microorganisms
  37. SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies
    Sabine Haggenburg, Quincy Hofsink, Caroline E. Rutten, Inger S. Nijhof, Mette D. Hazenberg, Abraham Goorhuis · 2022 · Seminars in Hematology
  38. DNA origami vaccine nanoparticles improve humoral and cellular immune responses to infectious diseases
    Yang C. Zeng, Olivia J. Young, Qiancheng Xiong, Longlong Si, Min‐Wen Ku, Sylvie G. Bernier, Hawa Dembele, Giorgia Isinelli, Tal Gilboa, Zoe Swank et al. · 2026 · Nature Biomedical Engineering
  39. A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta
    Brandon Carter, Pinghan Huang, Ge Liu, Yuejin Liang, Paulo J.C. Lin, Bi‐Hung Peng, Lindsay G. A. McKay, Alexander Dimitrakakis, Jason C. Hsu, Vivian Tat et al. · 2023 · Frontiers in Immunology
  40. Cross-Neutralizing Breadth and Longevity Against SARS-CoV-2 Variants After Infections
    Yukiya Kurahashi, Silvia Sutandhio, Koichi Furukawa, Lidya Handayani Tjan, Sachiyo Iwata, Shigeru Sano, Yoshiki Tohma, Hiroyuki Ohkita, Sachiko Nakamura, Mitsuhiro Nishimura et al. · 2022 · Frontiers in Immunology
  41. SARS-CoV-2-specific immune responses converge in kidney disease patients and controls with hybrid immunity
    Muriel Aguilar-Bretones, Yvette den Hartog, Laura L.A. van Dijk, S. Reshwan K. Malahe, Marjolein Dieterich, Hector Tejeda Mora, Yvonne M. Mueller, Marion Koopmans, Marlies E. J. Reinders, Carla C. Baan et al. · 2024 · npj Vaccines
  42. Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection
    Guidenn Sulbarán, Pauline Maisonnasse, Axelle Amen, Grégory Effantin, Delphine Guilligay, Nathalie Dereuddre‐Bosquet, Judith A. Burger, Meliawati Poniman, Marloes Grobben, Marlyse Buisson et al. · 2022 · Cell Reports Medicine
  43. Safety, immunogenicity and protective effectiveness of heterologous boost with a recombinant COVID-19 vaccine (Sf9 cells) in adult recipients of inactivated vaccines
    Wenxin Luo, Jiadi Gan, Zhu Luo, Shuangqing Li, Zhoufeng Wang, Jiaxuan Wu, Huohuo Zhang, Jinghong Xian, Ruixin Cheng, Xiumei Tang et al. · 2024 · Signal Transduction and Targeted Therapy
  44. Protective mucosal SARS-CoV-2 antibodies in the majority of the general population in the Netherlands
    Marije K. Verheul, Joanna Kaczorowska, Marloes I. Hofstee, Rutger M. Schepp, Gaby P. Smits, Dewi Wessels Beljaars, Marjan Kuijer, Wendy Schuin, Irene Middelhof, Denise Wong et al. · 2024 · Mucosal Immunology
  45. Comparison of the Development of SARS-Coronavirus-2-Specific Cellular Immunity, and Central Memory CD4+ T-Cell Responses Following Infection versus Vaccination
    Kevin M. Dennehy, Eva Loell, Christine Dhillon, Johanna-Maria Classen, Tobias Dominik Warm, Lukas Schuierer, Alexander Hyhlik-Dürr, Christoph Römmele, Yvonne Goßlau, Elisabeth Kling et al. · 2021 · Vaccines
  46. Th1-dominant cytokine responses in kidney patients after COVID-19 vaccination are associated with poor humoral responses
    Yvette den Hartog, S. Reshwan K. Malahe, Wim J. R. Rietdijk, Marjolein Dieterich, Lennert Gommers, Daryl Geers, Susanne Bogers, Debbie van Baarle, Dimitri Adriaan Diavatopoulos, A. Lianne Messchendorp et al. · 2023 · npj Vaccines
  47. Unbiased immunome characterisation correlates with COVID-19 mRNA vaccine failure in immunocompromised adults
    Juan H-Vázquez, Paloma Cal‐Sabater, Elisa Arribas‐Rodríguez, Aida Fiz‐López, Cándido Perez-Segurado, Álvaro Martín‐Muñoz, Ángel De Prado, Ignacio de la Fuente Graciani, Sonia Pérez González, Sara Gutiérrez et al. · 2024 · Frontiers in Immunology
  48. Early protective effect of a (“pan”) coronavirus vaccine (PanCoVac) in Roborovski dwarf hamsters after single-low dose intranasal administration
    Mohammed O. Abdelaziz, Martin J. Raftery, Julian Weihs, Olivia Bielawski, Richard Edel, Julia K.C. Köppke, Daria Vladimirova, Julia Maria Adler, Theresa C. Firsching, Anne Voß et al. · 2023 · Frontiers in Immunology
  49. Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates
    Patricia Pérez, Guillermo Albericio, David Astorgano, Sara Flores, Cristina Sánchez-Corzo, Pedro J. Sánchez‐Cordón, Joanna Luczkowiak, Rafael Bastos Delgado, José M. Casasnovas, Mariano Estéban et al. · 2023 · Frontiers in Immunology
  50. Durability of COVID-19 vaccine induced T-cell mediated immune responses measured using the QuantiFERON SARS-CoV-2 assay
    2022
  51. Antigen–Antibody Complex-Guided Exploration of the Hotspots Conferring the Immune-Escaping Ability of the SARS-CoV-2 RBD
    Kit-Man Fung, Shu-Jung Lai, Tzu-Lu Lin, Tien‐Sheng Tseng · 2022 · Frontiers in Molecular Biosciences
  52. Renaissance of antiviral CD8+ T cell immunity in vaccination and disease
    Victor Appay, Takuya Yamamoto, Asier Sáez‐Cirión · 2026 · Nature reviews. Immunology
  53. Architecture of the SARS-CoV-2-specific T cell repertoire
    Ksenia V. Zornikova, Saveliy Andreevich Sheetikov, Alexander Yu Rusinov, Rustam N. Iskhakov, Боголюбова Аполлинария Васильевна · 2023 · Frontiers in Immunology
  54. A multiantigenic Orf virus-based vaccine efficiently protects hamsters and nonhuman primates against SARS-CoV-2
    Alena Reguzova, Melanie Müller, Felix Pagallies, Dominique Julien Burri, Ferdinand Salomon, Hanns-Joachim Rziha, Zsofia Bittner-Schrader, Babs E. Verstrepen, Kinga P. Böszörményi, Ernst J. Verschoor et al. · 2024 · npj Vaccines
  55. Long Term Accuracy of SARS-CoV-2 Interferon-γ Release Assay and its Application in Household Investigation
    Kanagavel Murugesan, P. Jagannathan, J. Altamirano et al. · 2021 · medRxiv
  56. Human Coronaviruses: Counteracting the Damage by Storm
    Dewald Schoeman, Burtram Clinton Fielding · 2021 · Viruses
  57. SARS‐CoV‐2 infection induces thymic atrophy mediated by IFN‐γ in hACE2 transgenic mice
    Zaigham Abbas Rizvi, Srikanth Sadhu, Jyotsna Dandotiya, Puja Sharma, Akshay Binayke, Virendra Singh, Vinayaka Das, Ritika Khatri, Rajesh Kumar, Sweety Samal et al. · 2024 · European Journal of Immunology
  58. Clonal structure and the specificity of vaccine-induced T cell response to SARS-CoV-2 Spike protein
    Saveliy Andreevich Sheetikov, Alexandra A. Khmelevskaya, Ksenia V. Zornikova, Ivan V. Zvyagin, Alina S. Shomuradova, Yana V. Serdyuk, Naina T. Shakirova, Iuliia O. Peshkova, Aleksei Titov, Dmitrii S. Romaniuk et al. · 2024 · Frontiers in Immunology
  59. Gag Virus-like Particles Functionalized with SARS-CoV-2 Variants: Generation, Characterization and Recognition by COVID-19 Convalescent Patients’ Sera
    Arnau Boix‐Besora, Francesc Gòdia, Laura Cervera · 2023 · Vaccines
  60. Developing dendritic cell for SARS-CoV-2 vaccine: Breakthrough in the pandemic
    Jonny Jonny, Terawan Agus Putranto, Raoulian Irfon, Enda Cindylosa Sitepu · 2022 · Frontiers in Immunology
  61. Booster Dose of SARS-CoV-2 mRNA Vaccine in Kidney Transplanted Patients Induces Wuhan-Hu-1 Specific Neutralizing Antibodies and T Cell Activation but Lower Response against Omicron Variant
    Andrea Del Mastro, S. Picascia, L. D'Apice et al. · 2023 · Viruses
  62. The adaptation of SARS-CoV-2 to humans
    Eduardo Tosta · 2021 · Memórias do Instituto Oswaldo Cruz
  63. Vaccine-Induced T-Cell and Antibody Responses at 12 Months after Full Vaccination Differ with Respect to Omicron Recognition
    Franz Mai, Johann Volzke, Emil Christian Reisinger, Brigitte Müller‐Hilke · 2022 · Vaccines
  64. T cells step up after SARS-CoV-2 vaccination with B cell depletion
    T. Berger, B. Kornek · 2021 · Nature Reviews Neurology
  65. Design of a Multi-Valent SARS-CoV-2 Peptide Vaccine for Broad Immune Protection via Deep Learning
    Ziyan Feng, Xuelian Pang, Qian Xu, Zijie Gu, Shiliang Li, Lili Zhu, Honglin Li · 2025 · Engineering
  66. COVID-19 Vaccines—All You Want to Know
    Akira A. Shishido, Ashley H. Barnes, Shivakumar Narayanan, Joel V. Chua · 2023 · Seminars in Respiratory and Critical Care Medicine
  67. The spike-specific TCRβ repertoire shows distinct features in unvaccinated or vaccinated patients with SARS-CoV-2 infection
    Eleonora Vecchio, Salvatore Rotundo, Claudia Veneziano, Antonio Abatino, Ilenia Aversa, Raffaella Gallo, Caterina Giordano, Francesca Serapide, Paolo Fusco, Giuseppe Viglietto et al. · 2024 · Journal of Translational Medicine
  68. EpiCurator: an immunoinformatic workflow to predict and prioritize SARS-CoV-2 epitopes
    Cristina dos Santos Ferreira, Yasmmin Martins, Rangel Celso Souza, Ana Tereza Ribeiro de Vasconcelos · 2021 · PeerJ
  69. Mapping the immunopeptidome of seven SARS-CoV-2 antigens across common HLA haplotypes
    Asolina Braun, Louise C. Rowntree, Ziyi Huang, Kirti Pandey, Nikolas H Thuesen, Chen Li, Jan Petersen, Dene R. Littler, Shabana Raji, Thi H. O. Nguyen et al. · 2024 · Nature Communications
  70. Immune responses to human respiratory coronaviruses infection in mouse models
    Zhen Zhuang, Donglan Liu, Jing Sun, Fang Li, Jincun Zhao · 2021 · Current Opinion in Virology
  71. Next-generation probiotic Bacteroides. dorei: Improving the efficacy of COVID-19 vaccinations
    Siqin He, Si‐Min Lu, Yuanming Huang, Liqiong Song, Tao Yang, Yuchun Xiao, Zhihong Ren · 2024 · Journal of Functional Foods
  72. Preserved T-cell response in anti-CD20-treated multiple sclerosis patients following SARS-CoV-2 vaccination
    Simon Faissner, Neele Heitmann, Ricarda Rohling, Ulaş Ceylan, Marielena Bongert, Carlos Plaza‐Sirvent, Corinna Sophie Marheinecke, Xiomara Pedreiturria, Ilya Ayzenberg, Kerstin Hellwig et al. · 2022 · Therapeutic Advances in Neurological Disorders
  73. Is vaccination necessary for COVID-19 patients? A retrospective cohort study investigating reinfection rates and symptomatology in a tertiary hospital
    Ferhat Arslan, Burcu Isık Goren, Begümhan Baysal, Haluk Vahaboğlu · 2021 · Expert Review of Vaccines
  74. A single dose of COVID-19 vaccine induces a strong T cell and B cell response in healthcare professionals recovered from SARS-CoV-2 infection
    Paula Laranjeira, Tiago Rodrigues, Ana Silva, Pedro Barbosa, Teresa Reis, Cristiana Lopes, Aryane Cruz Oliveira Pinho, Sandra Silva, Isabel Silva, Anabela Carvalho et al. · 2022 · Clinical and Experimental Medicine
  75. Evolutionary Pattern Comparisons of the SARS-CoV-2 Delta Variant in Countries/Regions with High and Low Vaccine Coverage
    Jiahao Zhang, Lin-qian Fan, Hanli Xu, Yuan-Hui Fu, Xiang-Lei Peng, Yan-Peng Zheng, Jie‐mei Yu, Jinsheng He · 2022 · Viruses
  76. Supplementing SARS-CoV-2 genomic surveillance with PCR-based variant detection for real-time actionable information, the Netherlands, June to July 2021
    Richard Molenkamp, Ewout B. Fanoy, Leonie Derickx et al. · 2021 · Eurosurveillance
  77. A SARS-CoV-2 RBD vaccine fused to the chemokine MIP-3α elicits sustained murine antibody responses over 12 months and enhanced lung T-cell responses
    James T. Gordy, Yinan Hui, Courtney Schill, Tianyin Wang, Fengyixin Chen, Kaitlyn Fessler, Jacob Meza, Yangchen Li, Alannah D. Taylor, Rowan E. Bates et al. · 2024 · Frontiers in Immunology
  78. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants
    Chun-Hsiang Chiu, Yu-Hsiu Chang, Chi‐Wei Tao · 2022 · Microbiology Spectrum
  79. Advancing ORFV‐Based Therapeutics to the Clinical Stage
    Matthias Helmold, Ralf Amann · 2025 · Reviews in Medical Virology
  80. Impact of a COVID-19 Outbreak in an Elderly Care Home after Primary Vaccination
    Elba Mauriz, José Pedro Fernández-Vázquez, Cristina Díez-Flecha, Sofía Reguero Celada, Tania Fernández‐Villa, Ana Fernández‐Somoano, Joan A. Caylà, Jesús A. Lozano-García, Ana María Vázquez Casares, Vicente Martín · 2023 · Vaccines
  81. First-in-Human Phase I Trial to Assess the Safety and Immunogenicity of an Orf Virus-Based COVID-19 Vaccine Booster
    Meral Esen, Johanna Fischer-Herr, Julian Justin Gabor, Marika Gaile, Wim Alexander Fleischmann, Geerten Willem Smeenk, Roberta Allgayer de Moraes, Sabine Bélard, Carlos Lamsfus Calle, Tamirat Gebru Woldearegai et al. · 2024 · Vaccines
  82. Pathogenesis of Graves’ Disease Determined Using Single-Cell Sequencing with Thyroid Autoantigen Peptide Stimulation in B Cells
    Genki Kobayashi, Takuro Okamura, Yoshitaka Hashimoto, Kimiko Sakai, Madoka Sumi, Dan Imai, Nobuko Kitagawa, Masahide Hamaguchi, Takahiro Tsujikawa, Shigeru Hirano et al. · 2025 · Cells
  83. Feline Infectious Peritonitis mRNA Vaccine Elicits Both Humoral and Cellular Immune Responses in Mice
    Terza Brostoff, Hannah P. Savage, Kenneth A. Jackson, Joseph Dutra, Justin H. Fontaine, Dennis J. Hartigan-O’Connor, Randy P. Carney, Patricia A. Pesavento · 2024 · Vaccines
  84. Altered cellular immune response to vaccination against SARS-CoV-2 in patients suffering from autoimmunity with B-cell depleting therapy
    Isabel Hodl, Clarissa Sallegger, Patrick Forstner, Nazanin Sareban, Martina Moritz, Barbara Dreo, Eduard Schulz, Angelika Lackner, Barbara Kleinhappl, Stefan Hatzl et al. · 2023 · Microbes and Infection
  85. IgG1 glycosylation highlights premature aging in Down syndrome
    Bianca M. M. Streng, Julie Van Coillie, Joanne Wildenbeest, Rob S. van Binnendijk, Gaby P. Smits, Gerco den Hartog, Wenjun Wang, Jan Nouta, Federica Linty, Remco Visser et al. · 2024 · Aging Cell
  86. Unravelling the diagnostic methodologies for SARS-CoV-2; the Indispensable need for developing point-of-care testing
    Erfan Shahbazi, Asma Moradi, Hamidreza Mollasalehi, Seyed Reza Mohebbi · 2024 · Talanta
  87. Nonconserved epitopes dominate reverse preexisting T cell immunity in COVID-19 convalescents
    Xin Wang, Jie Zhang, Maoshun Liu, Yuanyuan Guo, Peipei Guo, Xiaonan Yang, Bingli Shang, Min Li, Jinmin Tian, Ting Zhang et al. · 2024 · Signal Transduction and Targeted Therapy
  88. Intra-Host SARS-CoV-2 Evolution in the Gut of Mucosally-Infected Chlorocebus aethiops (African Green Monkeys)
    Lori A. Rowe, Brandon J. Beddingfield, Kelly A. Goff, Stephanie Z. Killeen, Nicole R. Chirichella, Alexandra Melton, Chad J. Roy, Nicholas J. Maness · 2022 · Viruses
  89. Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape
    Mary Bushman, R. Kahn, B. Taylor, M. Lipsitch, W. Hanage · 2021 · medRxiv
  90. Evaluation of T cell responses to naturally processed variant SARS-CoV-2 spike antigens in individuals following infection or vaccination
    Zixi Yin, Ji-Li Chen, Yongxu Lu, Beibei Wang, Leila Godfrey, Alexander J. Mentzer, Xuan Yao, Guihai Liu, Dannielle Wellington, Yiqi Zhao et al. · 2023 · Cell Reports
  91. Comparable antigen-specific T cell responses in vaccinees with diverse humoral immune responses after the primary and booster BBIBP-CorV vaccination
    Dong Wei, Yingying Chen, Xiaoqi Yu, Yangdian Lai, Wenxin Xu, Ping Ji, Zhitao Yang, Erzhen Chen, Xinxin Zhang, Ying Wang · 2022 · Emerging Microbes & Infections
  92. Evaluation of a commercial interferon-γ release assay for the detection of SARS-CoV-2 T-cell response after vaccination
    Imane Saad Albichr, Samy Mzougui, Arnaud Devresse, Hélène Georgery, Eric Jean Goffin, Nada Kanaan, Jean Cyr Yombi, Leïla Belkhir, Julien De Greef, Anaïs Scohy et al. · 2023 · Heliyon
  93. COVID-19 vaccination in cancer patients: Immune responses one year after the third dose
    Roberta Campagna, Federica Dominelli, Maria Antonella Zingaropoli et al. · 2024 · Vaccine
  94. Comparative effectiveness of allocation strategies of COVID-19 vaccines and antivirals against emerging SARS-CoV-2 variants of concern in East Asia and Pacific region
    2021
  95. Protective Immunity against Gamma and Zeta Variants after Inactivated SARS-CoV-2 Virus Immunization
    Marcílio Jorge Fumagalli, Luíza Antunes de Castro-Jorge, Thais Fernanda de Campos Fraga‐Silva, Patrick Orestes de Azevedo, Carlos Fabiano Capato, Bruna Amanda da Cruz Rattis, Natália Satchiko Hojo-Souza, Vitor Gonçalves Floriano, Júlia Teixeira de Castro, Simone Gusmão Ramos et al. · 2021 · Viruses
  96. The Time-Dependent Association of Torque Teno Virus Load with the Level of SARS-CoV-2 S1 IgG Antibodies Following COVID-19 Vaccination in Kidney Transplant Recipients
    Céline Imhof, A. Lianne Messchendorp, Debbie van Baarle, Ron T. Gansevoort, Coretta van Leer‐Buter, Jan‐Stephan Sanders · 2023 · Viruses
  97. Donor selection for adoptive cell therapy with CD45RA− memory T cells for patients with coronavirus disease 2019, and dexamethasone and interleukin-15 effects on the phenotype, proliferation and interferon gamma release
    Karima Al‐Akioui‐Sanz, Bárbara Pascual-Miguel, Mariana Díaz‐Almirón, Carmen Mestre‐Durán, Alfonso Navarro‐Zapata, Laura Clares Villa, Carla Martín-Cortázar, José Luis Vicario, Miguel Ángel Moreno, A. Balas et al. · 2022 · Cytotherapy
  98. Waning antibody levels after vaccination with mRNA BNT162b2 and inactivated CoronaVac COVID-19 vaccines in Hong Kong blood donors
    S. Kwok, Samuel M. S. Cheng, J. Leung · 2021 · medRxiv
  99. Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study
    Lawrence Reiter, Johann Greffrath, Bian Zidel, Mario Ostrowski, Jennifer L. Gommerman, Shabir Ahmed Madhi, Richard Tran, Natalia Martín‐Orozco, Rajesh Krishnan Gopalakrishna Panicker, Curtis Cooper et al. · 2024 · Scientific Reports
  100. Characterization of SARS-CoV-2 public CD4+ αβ T cell clonotypes through reverse epitope discovery
    E. Rosati, M. Pogorelyy, Anastasia A. Minervina · 2021 · bioRxiv